ESTRO 2024 - Abstract Book

S2471

Clinical - Urology

ESTRO 2024

at 3-mos (92%). The most represented risk-group was UIR (52%), followed by favourable-intermediate risk (FIR, 29%), HR (14%), and low-risk (LR, 5%). HT was prescribed to 47% (n=124) of the pts: 72 pts treated with Bicalutamide 150 mg (short-term, 6 mos) and 52 pts undergoing LHRH analogues (long-term, 24-36 mos). The overall treatment time (OTT) exceeded 17 days in 87 pts (33%). A prostate volume >80cc was reported in 19% of cases. Previous TURP was reported for 22% of the study population. 35% had alpha-blocker therapy ongoing at baseline. The median IPSS score at baseline was 7, >12 for 27% of the population. The median IPSS doubled at RT-end (score=14), and then gradually decreased to baseline values at 6 mos. For pts observed up to 2-years, the median IPSS value was slightly higher than the baseline (score=9). Acute GU G2+ toxicity events were recorded for 82 pts, while late GU G2+ events for 14 pts. Acute GI G2+ toxicity events were recorded for 6 pts, while late GI G2+ events for 14 pts. UB scores dropped at RT-end (mean value 65 vs 77 at baseline), but a gradual satisfactory recovery was reported already at 6 mos (78) and persisting up to 2-years (75). UF mean scores did not significantly change along the timepoints: 88 at baseline, 86 at RT-end, 87 at 1-year, and 81 at 2-years. BB slightly dropped at RT-end (mean value 71 vs 79 at baseline), with a complete recovery already at 3-mos (82) after treatment and stable up to 2 years (78). BF trend overlapped with the BB one: mean score 86 at baseline, 76 at RT-end, 87 at 3-mos, 87 at 1-year, and 85 at 2-years. SB dropped at 1-year (mean score 39 vs 52 at baseline), with similar values at 2-years (42). SF dropped at 18-mos (mean score 24 vs 39 at baseline), with similar values at 2-years (29). Baseline SB and SF values reflect the median age and the high percentage of HT prescriptions. Figure 1 depicts the RTOG GU trend and the UB score trends. Figure 2 depicts the RTOG GI trend and the BB score trends.

Fig. 1

Fig.2